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Abstract
Uveal melanoma is a clinically distinct and particularly lethal subtype of melanoma originating 
from melanocytes in the eye. Here, we performed multi-region DNA sequencing of primary uveal 
melanomas and their matched metastases from 35 patients. We observed novel driver mutations 
and established the order in which these and known driver mutations undergo selection. 
Metastases had genomic alterations distinct from their primary tumors, and metastatic 
dissemination sometimes occurred early during the development of the primary tumor. Our study 
offers new insights into the genetics and evolution of this melanoma subtype, providing potential 
biomarkers for progression and therapy.
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Multi-region sequencing of 35 primary uveal melanomas and their matched metastases yields new 
insights into the genetics and evolution of these tumors and provides potential biomarkers for 
progression and therapy.
Uveal melanomas comprise 5% of melanomas in the US1. They derive from melanocytes in 
the choroid, iris, or ciliary body of the eye and constitute the most common eye cancer. Ten-
year mortality is 50%, markedly higher than most other melanoma subtypes2,3, and there 
currently are no effective treatment options for patients with metastatic disease4–6. An 
improved understanding of how uveal melanoma progresses from primary to metastatic 
disease promises to identify crucial pathogenic steps that could inform the development of 
new modalities of treatment and prognostication.
Several large-scale sequencing efforts have catalogued the genomic landscape of primary 
uveal melanoma7–10 and revealed a suite of genetic alterations distinctive from other 
melanoma subtypes11. Uveal melanomas commonly harbor mutations that activate the G-
protein alpha-q signaling cascade, affecting GNAQ12, GNA1113, PLCB414, or CYSLTR215 
that, with rare exceptions, occur in a mutually exclusive pattern. They additionally have 
secondary somatic alterations affecting BAP110,16, SF3B18, or EIF1AX9 that tend to also to 
occur exclusive of each other. Further, uveal melanomas have recurrent copy number 
alterations involving gains of chromosomes 6p and 8q as well as losses of chromosomes 1p, 
3, 6q, 8p, and 16q. BAP1 constitutes the major tumor suppressor gene on chromosome 3, 
and MYC is possibly the oncogene on chromosomal arm 8q. It is unclear which genes drive 
the other copy number changes.
In contrast to primary uveal melanoma, few uveal melanoma metastases have been 
sequenced to date17- particularly lacking are studies of primary tumors and patient-matched 
metastases. Uveal melanomas have a propensity to metastasize via hematogenous routes to 
the liver, a distant site with respect to their origins in the eye. There is a latency between 
removal of the primary tumor and the emergence of metastases that ranges from months to 
decades4,18. In order to better understand the evolution of metastatic uveal melanoma, we 
performed multi-region DNA sequencing of primary uveal melanomas and patient-matched 
metastases.
Results
We sequenced non-lesional reference tissue, one or more regions of the primary tumor, and 
corresponding liver metastases from 35 patients with metastatic uveal melanoma 
(Supplementary Table 1). The majority of tissues were microdissected from archival paraffin 
blocks. Sequencing libraries from formalin-fixed paraffin-embedded (FFPE) tissues have 
lower complexity19, and we therefore elected to perform targeted sequencing of a panel of 
500 genes commonly involved in cancer (Supplementary Table 2), allowing us to sequence a 
smaller genomic footprint at substantially higher coverage. On average, each sample was 
sequenced to 423-fold unique coverage, enabling sensitive mutation detection and helping to 
overcome the well-documented20 challenge of detecting certain BAP1 mutations.
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A workflow to delineate the evolution of metastatic uveal melanoma.
Our workflow to deduce the genetic evolution of metastatic uveal melanoma is illustrated by 
the example case (A11) shown in Figure 1. From this patient, we microdissected two 
histologically distinct areas of the primary melanoma and part of the optic nerve, which 
served as a source of non-lesional reference tissue (Fig. 1a). Metastatic tissue was obtained 
from the patient’s liver core biopsy (Fig. 1a).
Only two somatic point mutations were identified, reflecting the low mutation burden that is 
typical of this melanoma subtype. Both mutations, a heterozygous, gain-of-function GNA11 
variant and a hemizygous, loss-of-function BAP1 variant, were shared between all three 
melanoma samples (Fig. 1b). To determine the allelic status of mutations, we 
bioinformatically estimated the fraction of neoplastic cells in each melanoma region. The 
blue lines in Figure 1b denote the expected mutant allele fractions where a heterozygous 
mutation would be expected to reside with fading zones that indicate the 95% confidence 
intervals. The loss of heterozygosity of the BAP1 mutation is evident by its mutant allele 
fraction falling outside those zones in all three samples.
We next inferred copy number alterations using the software package CNVkit21 (Fig. 1c). In 
the example case, some copy number alterations were shared between all samples, including 
a deletion of chromosome 3 that encompassed the BAP1 gene and thus explains how the 
BAP1 mutation became hemizygous. A loss of chromosomal arm 9p and a gain of 
chromosomal arm 8q were also present in each melanoma region (Fig. 1c).
By contrast, some copy number alterations were exclusive to certain tissues. For instance, 
there was a superimposed homozygous deletion encompassing the CDKN2A gene that was 
only present in the unpigmented area of the primary melanoma (Mel1) and the metastasis 
(Supplementary Fig. 1a). Also, the amplitudes of 8q gain differed among the melanoma 
tissues (Supplementary Fig. 1b) - the pigmented area of the primary (Mel2) had 5 absolute 
copies, while the unpigmented area (Mel1) had 9 absolute copies, and the metastasis had 11 
absolute copies. These observations indicate stepwise deletion of CDKN2A paralleled by 
stepwise amplification of 8q during the evolution of this case.
The distribution of somatic mutations and copy number changes among the three tumor 
areas made it possible to delineate the sequential order in which they arose during tumor 
evolution. All three tumor samples shared the GNA11Q209L mutation, bi-allelic BAP1 
alterations, mono-allelic deletion of CDKN2A, and gain of at least three copies of 
chromosomal arm 8q – this indicates that these alterations arose comparatively early and 
thus reside on the trunk of the evolutionary tree (Fig. 1d). The Mel1 area of the primary 
tumor and the metastasis shared a homozygous deletion of CDKN2A and additional levels 
of 8q gain, placing these somatic alterations on a shared branch of the evolutionary tree (Fig. 
1d). Finally, the metastasis harbored the highest amplitude of 8q gain, placing these extra 
levels of 8q gain on the terminal branch of the evolutionary tree (Fig. 1d).
In aggregate, activation of GNA11, bi-allelic loss of BAP1, low-level gain of 8q, and mono-
allelic loss of CDKN2A occurred in the most recent common ancestral clone. A subclone 
with higher levels of 8q gain and bi-allelic loss of CDKN2A emerged in the primary (Mel1), 
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and this clone gave rise to a liver metastasis with even higher levels of 8q gain (Fig. 1d). The 
equivalent detailed evolution of the remaining 34 cases is available in the supplementary 
dataset on FigShare (https://doi.org/10.6084/m9.figshare.6845675.v1).
The genomic landscapes of primary and metastatic uveal melanoma.
We next annotated the driver mutations in each sequenced region from all 35 patients’ 
tumors. As expected, based on prior studies, we observed mutually exclusive mutations 
involving genes in the Gαq signaling cascade as well as alterations affecting BAP1, SF3B1, 
and EIF1AX that tended to not overlap. However, in contrast to prior studies, we found a 
long tail of additional mutations (Fig. 2) that included loss-of-function mutations affecting 
CDKN2A, PBRM1, PIK3R2, and PTEN, loss-of-heterozygosity over the GNAQ locus, and 
gain-of-function mutations affecting EZH2, PIK3CA, and MED12. The majority of these 
alterations were in just one region of the primary tumor or private to their metastases 
(designated in Figure 2 by the faded tiles), indicating that they arose later during 
progression, after mutational activation of Gαq and mutations of BAP1, SF3B1, and 
EIF1AX. These mutations are thus considered tertiary driver mutations, likely explaining 
why they were not apparent in prior bulk sequencing of primary uveal melanomas.
Early mutational activation of the Gαq signaling pathway is pathognomonic of uveal 
melanoma.
Activation of Gαq signaling was ubiquitous with mutations affecting GNA11, GNAQ, 
CYSTLR2, or PLCB4 in a mutually exclusive pattern in all 35 cases in our cohort, 
consistent with prior findings. The mutations activating the Gαq signaling pathway were 
always shared among all samples from a given patient, indicating that they undergo selection 
early and are required for tumor formation (Supplementary Fig. 2a). This is also consistent 
with the recent finding that these mutations are common in choroidal nevi, which is likely a 
precursor for a subset of uveal melanomas22. Gαq-signaling-pathway mutations were 
heterozygous in the majority of cases. However, in six cases, GNAQ mutations were 
hemizygous or homozygous (Supplementary Fig. 2b) as a consequence of additional genetic 
alterations that eliminated the wild-type allele. Loss-of-heterozygosity of mutant GNAQ 
tended to take place later during progression (Supplementary Fig. 2b). Preferential 
expression of mutant over wild-type GNAQ has been observed previously23, and our data 
offer a mechanism as to how this can occur.
Uveal melanomas with SF3B1 or EIF1AX mutations acquire additional oncogenic 
mutations during metastatic progression.
We next sought to investigate the relative timing of BAP1, SF3B1, and EIF1AX mutations. 
Patients whose uveal melanomas have SF3B1 or EIF1AX mutations tend to have a better 
prognosis than those with BAP1 mutations7. Likely because our cohort consisted entirely of 
metastatic uveal melanomas, SF3B1- and EIF1AX- mutant cases were underrepresented (n 
= 7). In general, the BAP1, SF3B1, and EIF1AX mutations did not co-occur. However, one 
EIF1AX-mutant tumor also had bi-allelic BAP1 mutations (Supplementary Fig. 3a). This 
case was further unusual because the EIF1AX mutation resided at codon 70, a site that is 
recurrently mutated but less frequently affected than the N-terminal region of EIF1AX. 
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Finally, the Gq-pathway mutation in this atypical case involved CYSTLR2, which is rare 
compared to GNAQ and GNA11 mutations.
The cases with SF3B1 or EIF1AX mutations tended to have additional oncogenic 
alterations. Two had homozygous CDKN2A deletions, three had PI3-kinase pathway 
mutations (PTENC218*, PIK3CAH1047R, and PIK3R2N485S), and one had a MED12 hotspot 
mutation (Supplementary Fig. 3). In one EIF1AX-mutant case, we sequenced two areas of 
primary tumor, and the more histologically advanced area acquired a deletion of 
chromosome 3 (Supplementary Fig. 3b) – this was notable because it has been proposed that 
primary tumors without monosomy 3 may progress towards a more malignant stage by 
losing chromosome 324.
The SF3B1 and EIF1AX mutations were predominately truncal, whereas the additional 
oncogenic mutations were more often branchial. This pattern suggests that SF3B1 and 
EIF1AX mutations undergo selection early but may require additional oncogenic alterations 
to complement their likely limited ability to drive disease progression and metastatic 
dissemination.
Selection to disrupt chromatin remodeling factors begins early and continues throughout the 
evolution of metastatic uveal melanoma.
BAP1 mutations were expectedly common in our cohort of uveal melanomas that became 
metastatic and were usually shared among all samples from a given patient, placing them on 
the trunks of evolutionary trees (Fig. 3a). These observations suggest that bi-allelic BAP1 
mutations tend to precede metastatic dissemination.
There were, however, two cases in which BAP1 alterations had a different distribution 
between primary tumors and their metastases (Fig. 3b,c). In case A29, the primary tumor 
had a frameshift mutation and a deletion affecting BAP1, but its metastasis had only very 
few reads of the frameshift mutation and did not have a deletion on chromosome 3 (Fig. 3b). 
In case A13 (Fig. 3c), the primary tumor and the metastasis shared a point mutation in 
BAP1, but only the primary had eliminated the second allele of BAP1, whereas the mutation 
in the metastasis remained heterozygous. The metastases from cases A29 and A13 were both 
negative for BAP1 protein by immunohistochemistry (Fig. 3d), suggesting that either BAP1 
was silenced epigenetically, or the mutation escaped detection by our methods. Overall, 
these two cases raise the possibility that bi-allelic loss of BAP1 is not absolutely required for 
metastatic dissemination. This would be consistent with anecdotal reports of monosomy 3 
occurring later in the evolution of uveal melanoma25,26; however, further studies will be 
necessary to confirm whether this is true.
We also observed mutations in other chromatin remodeling factors, including hemizygous, 
loss-of-function mutations in PBRM1 and gain-of-function EZH2 mutations (Fig. 3e). 
PBRM1 encodes a critical subunit of the SWI/SNF chromatin remodeling complex, and 
EZH2 encodes the enzymatic subunit of Polycomb repressive complex 2 (PRC2)27. BAP1 is 
a negative regulator of PRC1 which activates PRC2, so BAP1 loss is thought to promote 
PRC2 activation. The SWI/SNF chromatin remodeling complex also opposes PRC2 activity 
in maintaining cell-state appropriate chromatin modifications28–30; therefore, the alterations 
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in PBRM1 and EZH2 likely shift the balance of chromatin remodeling activity further 
towards PRC2 dominance. In contrast to BAP1 mutations, which occurred earlier in most 
cases, mutations affecting PBRM1 or EZH2 occurred later, as they were generally not 
shared among all tumor areas of a given patient.
Copy number gains of chromosome 8q arise in the primary tumor and ramp up during 
metastatic progression.
Copy number gains of chromosome 8q were present in nearly every case and were typically 
shared among the different tumor areas of a given patient (Fig. 4a), suggesting that they 
occur early during evolution of the primary tumor, prior to metastatic dissemination, as 
previous data have suggested31. There were three exceptions to this pattern in which copy 
number gains were not shared in every tumor area (Fig. 4b), indicating that it is at least 
possible for metastatic dissemination to precede 8q gain.
We delved deeper into the amplitudes of 8q gain and observed that the copy number of 8q 
tended to increase from primaries to metastases. For instance, as described in case A11, one 
region of the primary tumor had 5 copies of 8q, while another region of the primary tumor 
had 9 copies, and the metastasis had 11 copies (Fig. 4a and Supplementary Fig. 1b). In other 
examples, the primary tumor for case A61 had 4 copies of 8q, and the metastasis had 11 
copies (Fig. 4a and Supplementary Fig. 4a), and in case A06, the primary tumor had 4 
copies of chromosomal arm 8q, while the metastasis had 9 copies (Fig. 4a and 
Supplementary Fig. 4b). Overall, metastases had more copies of 8q than their corresponding 
primary tumors in most patients, with an average of 6 versus 4 copies (P = 0.002 two-tailed 
t-test) (Fig. 4c). We validated our sequencing-based copy number estimates by measuring 
allelic imbalance and assessing copy number with independent technologies, including 
multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ 
hybridization (FISH) (Supplementary Fig. 4c–e). The findings of these methods were 
concurrent and indicate progressive increase of 8q copy number during progression to 
metastatic disease.
The sequential order of genetic alterations during metastatic progression.
We deduced the sequential order in which somatic alterations undergo selection during the 
evolution of metastatic uveal melanoma by calculating how often a given alteration resided 
on the trunk versus the branch of each evolutionary tree (Fig. 5a). This analysis confirmed 
that Gαq-pathway mutations are the earliest mutations to undergo selection, followed by 
gain of chromosomal arm 8q as well as BAP1, SF3B1, or EIF1AX mutations. Selective 
pressures continue to operate on these pathways at comparatively later points in the 
progression cascade by way of GNAQ loss-of-heterozygosity, additional chromatin 
remodeling mutations, and further ramp-up of 8q copy number (Fig. 5a). Copy number 
alterations affecting chromosomal arms 16q, 8p, 1p, 6p, and 6q underwent selection at 
intermediate points in the evolutionary cascade (Fig. 5a).
Finally, we compared the frequency of somatic alterations between primaries and 
metastases. Most somatic alterations were somewhat enriched in metastases, but only copy 
number changes of 6q, 1q, and high-level gains of 8q (copy number increase by at least 3 
Shain et al. Page 6
Nat Genet. Author manuscript; available in PMC 2019 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
copies) reached statistical significance (Fig. 5b). In particular, gains of 1q were frequent in 
our cohort compared to prior studies on primary uveal melanomas, consistent with their 
emergence later during progression (Fig. 5 and Supplementary Fig. 5). Further studies will 
be needed to elucidate the gene(s) driving the selection of these aberrations.
Correlations with clinical outcomes.
Genomic studies of primary uveal melanomas have revealed several mutations with 
prognostic value8–10. Our cohort was underpowered to discover new biomarkers of this type, 
but capitalizing on a unique aspect of our study, we instead investigated whether specific 
evolutionary routes of progression correlated with clinical outcomes.
As all of our patients ultimately developed metastatic disease, we assessed correlations 
between clinical outcomes (disease-free survival, survival after metastasis, and overall 
survival) and features of their genetic evolution (i.e. metrics of the phylogenetic trees, such 
as individual and combined lengths of trunk and branches as well as branch separation; see 
Methods) (Supplementary Fig. 6a,b). The overarching goal was to investigate whether 
certain evolutionary trajectories were associated with clinical outcomes, as was recently 
shown to be true in renal cell carcinoma32.
Patients whose trees had longer metastasis branches and shorter primary branches tended to 
have better disease-free survival (Supplementary Fig. 6c) – this comparison was statistically 
significant by itself (R = 0.34, P = 0.046), though it did not remain significant after 
correcting for multiple-hypothesis testing. If this finding is validated in larger cohorts, it 
likely reflects the fact that some uveal melanomas require more genetic alterations to 
develop clinically detectable metastases, and these uveal melanomas have better survival 
metrics reflecting the time required to incrementally acquire the necessary set of alterations.
Discussion
Our study shows that uveal melanomas continue to genetically evolve as they progress from 
primary to metastatic disease, as indicated by the fact that metastases tend to have more 
oncogenic mutations than primary tumors. This contrasts with most other tumor types for 
which metastases are genetically similar to primary tumors33,34. One peculiar aspect of 
uveal melanoma is that in many cases metastases develop after a long period of latency after 
successful eradication of the primary tumor – this latency period may partially reflect the 
additional time needed to acquire the necessary mutations for growth at the distant site (Fig. 
6). In addition to having more oncogenic alterations, metastases also acquire distinct 
oncogenic alterations, including additional copies of chromosomes 1q and 8q. This may 
reflect different selective pressures operating in the liver, the major organ in which 
metastases develop in uveal melanoma.
Prior sequencing studies of uveal melanoma mostly analyzed a single tissue sample from the 
primary tumor. Our multi-region sequencing of primaries and metastases revealed multiple 
novel mutations, expanding the catalog of driver mutations for this aggressive melanoma 
subtype. These novel mutations were more common in uveal melanomas with SF3B1 or 
EIF1AX mutations, and they possibly complement the otherwise limited ability of SF3B1 
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and EIF1AX mutations to drive metastatic disease. The earliest driver mutations in primary 
uveal melanoma are not easily druggable, but there is hope that some of the newly 
recognized mutations found in some metastases can be targeted therapeutically.
We also observed loss-of-heterozygosity of mutant GNAQ, but not GNA11, in multiple 
samples, indicating hidden complexity in oncogenic signaling through mutant Gαq subunits. 
The Q209 alterations in GNAQ and GNA11 abrogate their GTPase activity, similar to 
mutant RAS. RAS mutations also undergo loss-of-heterozygosity by a variety of 
mechanisms that shift the allelic balance towards the mutant allele35. Earlier studies using 
Sanger sequencing have reported increased frequency of GNA11 mutations in metastatic 
uveal melanomas, whereas GNAQ mutations are more common in benign lesions, such as 
blue nevi13. This led to the proposition that GNA11 mutations are more potent. The finding 
of recurrent loss-of-heterozygosity of GNAQ mutations later in progression may indicate 
that GNAQ, but not GNA11, requires a second hit to fully activate the pathway, which could 
explain the association with GNA11 mutations with more aggressive disease.
Uveal melanomas have been proposed to arise after an early, punctuated burst of mutations 
followed by a period of neutral evolution20. In our cohort, we found three cases in which 
metastatic dissemination preceded 8q gain and potentially two cases in which metastatic 
dissemination preceded bi-allelic loss of BAP1. These cases suggest that it is at least 
possible for metastatic dissemination to occur before the neoplasm has developed the full 
complement of oncogenic mutations (Fig. 6), though additional studies, focused on the 
earlier stages of neoplasia, will be needed to fully resolve the incipient events involved in the 
evolution of uveal melanoma. We also found multiple added driver mutations in the 
branches of phylogenetic trees, arguing against neutral evolution in the latter phases of 
evolution.
In summary, our study reveals the selective pressures operating on primary tumors and 
metastases during the evolution of uveal melanoma and offers candidate biomarkers for 
staging and prognosis.
Online Methods
Patient samples.
Primary and patient-matched metastatic uveal melanoma tissues were from the Ocular 
Tumor Division in the Copenhagen University Hospital. Most primary uveal melanomas 
were from archival (formalin-fixed paraffin-embedded) blocks of enucleated eyes, though 
some were derived from fresh biopsies, as indicated (Supplementary Table 1). All 
metastases were liver metastases. Among the metastatic tissues, most were derived from 
archival blocks of liver core biopsies with a subset derived from archival blocks of liver 
resections, as indicated (Supplementary Table 1). All metastases were treatment naïve. Most 
reference (normal) tissues were microdissected from non-lesional areas of the primary tumor 
blocks with some originating from patient-matched blood, as indicated (Supplementary 
Table 1).
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This retrospective study was approved by the regional ethical committee in Copenhagen, 
Denmark (H-2-2013-064) and the Danish Data Protection agency (RH-2015–167). All 
tissues were collected in accordance with the institutional review board with regard to 
informed consent.
The overarching design of this study is also described in the Life Sciences Reporting 
Summary.
Microdissection and DNA extraction.
All microdissections were performed with a scalpel under a dissection scope and guided by 
a pathologist with the intent to maximize tumor cell content. 10-μm unstained sections 
(between 4–10 levels) were used. Genomic DNA was isolated with Qiagen DNA FFPE 
Tissue Kit (p/n 56404). When possible, we microdissected multiple regions of the primary 
tumor. In total, we collected and sequenced 53 pieces of primary uveal melanoma, 36 pieces 
of uveal melanoma metastasis, and 35 normal (i.e. non-lesional) tissues.
DNA sequencing and analysis.
25–250 ng of genomic DNA was sheared (250 bp target fragment size) and prepared for 
Illumina sequencing as previously described36,37. As expected, the smaller FFPE-derived 
neoplasms had lower library complexities. We therefore elected to perform targeted 
sequencing of a panel of 538 genes commonly involved in cancer (see Supplementary Table 
2 for baits), favoring more samples and more coverage over a larger sequencing footprint. 
This decision did not hinder the overarching goal of the study, which was to delineate the 
order in which known driver mutations arise during the evolution of metastatic uveal 
melanoma. On average, each sample was sequenced to 423-fold de-duplicated coverage (see 
Supplementary Table 1 for more details). Baits were developed with the customized 
Nimblegen SeqCap EZdeveloper platform. Sequencing was performed on an Illumina HiSeq 
2500 instrument.
Alignment, grooming, and mutation calling were performed with the following software 
packages: Burrows-Wheeler Aligner (BWA), Genome Analysis Tool-Kit (GATK), Picard, 
and MuTect. Sequencing metrics for each sample are available in Supplementary Table 1.
CNVkit was used to infer copy number information. This software can be run in reference or 
reference-free mode. We elected to run CNVkit in reference mode, as this consistently 
produces higher quality copy number calls when references (i.e. normal tissues) are 
available. Two separate reference pools were generated for this study – non-neoplastic eye 
tissue and non-neoplastic liver tissue. The eye reference was used to infer copy number 
information from primary tumors whereas liver reference tissue was used to infer copy 
number information from metastases.
Driver gene calling.
The driver genes in each case are summarized in Figure 2. We include any mutation 
affecting GNAQ, GNA11, PLCB4, CYSTLR2, BAP1, EIF1AX, or SF3B1 – this is based on 
these genes’ previously described roles in driving uveal melanoma. We also include 
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alterations affecting CDKN2A, PBRM1, and EZH2 due to their recurrence in our study and 
known roles as cancer genes in other tumor types. Moreover, we include hotspot mutations 
affecting PIK3CA and MED12, which were observed once in our study but are common in 
pan-tumor analyses. Finally, we include inactivating mutations affecting PTEN and PIK3R2, 
which are prominent tumor suppressors in other cancers and are lost in a bi-allelic fashion in 
our study.
Copy number estimation.
To deduce the discrete levels for each copy number alteration, we first calculated the 
expected log ratios for each level of gain or loss. For example, a mono-allelic deletion 
should have a log2(tumor/reference) segmentation value of −1 (because log2(1/2) = −1); 
however, in practice, this is never observed because each tumor has some level of stromal 
cell contamination, and stromal cells do not harbor copy number alterations. We took into 
account stromal cell contamination for each sample by proportionally weighting the 
expected segment value for a given copy number alteration with the expected log2(stroma/
reference) from stromal cells (assumed to be 0) in that sample.
Supplementary dataset covering the evolution of all 35 cases.
In Figure 1, we present the detailed evolution of an example case, including the distribution 
of point mutations, copy number alterations, and allelic imbalances over each tumor region 
from a single patient. We analyzed all 35 cases in this cohort to the same level of detail, and 
we include the detailed evolution of the other 34 cases in the following supplementary 
dataset38 hosted at Figshare (https://doi.org/10.6084/m9.figshare.6845675.v1).
Phylogenetic tree construction.
Point mutation calls are available in Supplementary Table 3, and copy number calls are 
available in Supplementary Table 4. Phylogenetic trees were constructed as described for 
Figure 1 from the shared and private somatic alterations. All phylogenetic trees are rooted to 
the germline state. The trunk and branch lengths for each phylogenetic tree are provided in 
Supplementary Table 1. When multiple mutations occurred on the same segment of the 
phylogenetic tree, they are bracketed, serving as an indication that it is not possible to 
deduce the relative order in which they occurred.
Tumor cellularity inference.
Most tumors are infiltrated with stromal cells, resulting in a mixture of sequencing reads 
derived from stromal and tumor cells. It is important to accurately measure tumor cell 
content in order to ensure that sequencing depth is sufficiently powered to detect mutations 
and also to measure the zygosity of somatic mutations. We employed a series of 
bioinformatic approaches to estimate tumor cell content36,39. Specifically, copy number 
alterations induce allelic imbalances over germline heterozygous SNPs, and we used the 
extent of allelic imbalance to measure tumor cellularity. We also calculated tumor cell 
content based on somatic mutation allele fractions after taking into account the copy number 
status of the locus. When possible, tumor cell content was calculated from both germline 
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and somatic variant allele fractions to produce a consensus estimate (see Supplementary 
Table 1).
8q copy number inference.
In Supplementary Figure 4a,b, we inferred discrete levels of copy number gain over 
chromosomal arm 8q as described in the “Copy number estimation” section above. We 
validated these estimates several ways.
In Supplementary Figure 4c, we calculated the ratio of reads mapping to the major versus 
minor allele over heterozygous SNPs situated on chromosomal arm 8q. Here, the term 
“major allele” refers to the more abundant, or amplified, allele in the tumor. To calculate this 
ratio, we first subtracted out the reads emanating from stromal cells – these reads would 
have allelic ratios of 1:1, thereby diluting the overall ratio. The specific formula to determine 
the ratio of reads in the tumors cells that we used was as follows:
N= Ratio of the major to minor allele in tumor cells
S= Overall major allele read fraction
X= Fraction of tumor cells
N = 2*S − 1 / X−X*S
For higher level gains, there are several potential allelic combinations (see Supplementary 
Fig. 4c for a schematic); we therefore show the expected relationship between absolute copy 
number and major to minor allele ratios after considering all of these possibilities 
(Supplementary Fig. 4c, left panel). We next plotted the observed relationship between 
absolute copy number and major to minor allele ratios from our data (Supplementary Fig. 
4c, right panel). Note that the observed relationship closely mirrors the expected 
relationship. In particular, tumors with high levels of 8q gain were more likely to have 
greater ratios of major to minor allelic reads. In aggregate, the allelic ratios over 
chromosomal arm 8q support our absolute copy number inferences.
In Supplementary Figure 4d, we used multiplex ligation-dependent probe amplification 
(MLPA)40 to measure 8q levels in 8 primary tumors predicted to harbor between 2–6 copies 
of chromosomal arm 8q. DNA was extracted using the QIAamp DNA Micro Kit (Qiagen), 
followed by standard sodium acetate/ethanol precipitation for optimal purity. Probes were 
ligated to specific DNA sequences on chromosomes 1, 3, 6 and 8 using the SALSA MLPA 
KIT P027-B1 Uveal Melanoma (MRC-Holland). In addition, 12 reference probes were 
ligated to chromosomes 2, 4, 5, 10, 11, 12 13, 14, 15 and 18. The signal intensities of the 
various probes were measured using capillary electrophoresis on a Genetic Analyzer 3130xl 
(Applied Biosystems). The signal intensity of each probe was normalized to the signal 
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intensity of each reference probe and the relative amount of each target sequence was 
calculated using the Coffalyzer. Net data analysis software from MRC Holland. The y-axis 
of Supplementary Figure 4d depicts the ratio of 8q signal to other parts of the genome 
without copy number alterations. It is important to note that MLPA signals are subject to 
saturation at higher level gains, providing a relative (rather than an absolute) estimate of 
copy number. We observed a near perfect correlation (R = 0.97) between MLPA ratios and 
absolute copy number estimates from sequencing data, supporting our absolute copy number 
inferences.
In Supplementary Figure 4e, we performed fluorescence in situ hybridization (FISH) to 
validate copy number of chromosomal arm 8q. In the right panel, FISH was performed using 
probes targeting c-MYC (Vysis LSI MYC spectrum orange probe) and CEP12 (Vysis 
CEP12 spectrum green probe) (both probes from Abbott Molecular Inc). Slides were 
scanned with a fluorescence microscope (Carl Zeiss AxioImager.Z2) and analyzed using the 
Metafer4 v 3.8.12 software (Metasystems) per manufacturer’s instructions. Tumor-bearing 
areas were identified by a pathologist using the DAPI filter at low magnification (10× lens) 
with the aid of the H&E. All areas involving tumor cells were scanned and within this area 
cells, which did not overlap and had bright signals for the probes were used for enumeration. 
Nuclei that had complete absence of signals for the control probe (CEP12) were excluded. 
At least 30 cells were analyzed per case. In the left panel, the tumor specimens were placed 
in a culture medium immediately after surgery and analyzed. The following fluorescent 
probes were hybridized to the tissues: Telomeric probe for chromosome 1p (Vysis 
TelVysion 1p) and centromeric probes for chromosome 3 (CEP3 D3Z1), 6 (CEP6 D6Z1), 
and 8 (CEP8) (all probes from Abbott Molecular, Inc.; www.abbottmolecular.com). The 
probes were visualized and counted using a fluorescence microscope. At least 100 cells were 
evaluated by two technicians and copy number variations in more than 10% of the cells were 
used as a cut off. The six tumors analyzed with a centromeric 8 probe were chosen because 
they did not have copy number transitions across the centromere of chromosome 8. The 
copy number estimates from our sequencing data typically aligned with the mode counts 
from the FISH data (Supplementary Fig. 4e).
Statistics.
In Figure 1b, we calculated the fraction of tumor cells in each microdissected tissue 
(described above) – the blue lines are anchored at half of that value (i.e. the expected mutant 
allele fraction of a fully clonal, heterozygous somatic mutation). The fading zones represent 
the 95% confident intervals. This was calculated under the assumption that mutant reads are 
sampled randomly from the total pool of mutant alleles in our DNA input, and therefore the 
final mutant allele fraction should fall within a binomial distribution around the expected 
mutant allele fraction of a fully clonal, heterozygous somatic mutation. Under this 
assumption the standard deviation of this distribution is dependent upon the sequencing 
depth (SD) in that sample and tumor cellularity (TC) as follows: ((0.5*TC) – (0.5*TC)2) × 
SD)0.5. The 95% confidence interval was calculated by multiplying the standard deviation 
by 1.96. Finally, these confidence intervals were converted to fractions by dividing them by 
the total sequencing depth in that sample.
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In Figure 4c, we performed a two-tailed t-test, assuming equal variance, to compare the level 
of copy number gain of chromosomal arm 8q in primary tumors (n = 53) versus metastases 
(n = 36) (degrees of freedom = 87).
In Figure 5b, for the genomic alterations shown in Figure 5, we tabulated the number of 
times each occurred in metastases and primaries. We tested the probability that genomic 
alterations were enriched in metastases or primaries against the null hypothesis that the 
alterations should be equally distributed in each compartment. The P-values shown in Figure 
5 reflect two-tailed probabilities under the assumption that our sampling of genomic 
alterations fits a binomial distribution of enrichments dictated by sampling size. Adjustments 
for multiple-hypothesis testing were not performed.
In Supplementary Figure 6, we sought to identify significant associations between clinical 
outcomes and phylogenetic-tree features. We took several measurements of phylogenetic 
trees from each case (see Supplementary Fig. 6b), including tree height, trunk length, branch 
lengths, and branch separation. Next, we investigated whether any of these measurements 
correlated with disease-free survival, survival after metastasis, or overall survival. In total, 
we made 18 pairwise comparisons between the 6 phylogenetic-tree measurements and the 3 
clinical outcome datatypes. Each comparison comprised 35 data points, corresponding to 
each patient in the study. The correlations are shown as R-values (Pearson correlation 
coefficients) in Supplementary Figure 6b. We also performed a linear regression analysis to 
produce P-values for each correlation against the null hypothesis that the correlation 
coefficient (R-value) should be 0. Lastly, we report adjusted P-values, which were corrected 
for multiple-hypothesis testing using the Bonferroni correction.
Data availability.
The raw sequencing data are available at the European Genome Phenome Archive under 
accession EGAD00001004453.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1 |. The patterns of somatic alterations within a patient’s tumor areas provide insights in 
the sequential order in which they arose (example case A11)
a, H&E sections of the enucleation specimen show morphologically distinct areas. The 
metastatic tissue stemmed from a liver core biopsy of the patient. Dotted regions were 
microdissected for genomic analyses. b, Point mutations are stratified by their mutant allele 
fractions (MAFs) in the two regions of the primary tumor and the metastasis. The blue bars 
indicate the expected MAFs of fully-clonal, heterozygous mutations after accounting for 
stromal cell contamination, with shadings indicating confidence intervals where those 
mutations should reside. Note the presence of a GNA11Q209L mutation that is fully clonal 
and heterozygous in all samples. By contrast, the BAP1Y173C mutation has an elevated 
MAF, indicating that it underwent loss-of-heterozygosity. c, Heatmap displaying copy 
number increases (red) or decreases (blue) for each sample (rows) across the genome with 
chromosomal boundaries indicated. Additional details related to deletion of CDKN2A and 
gain of chromosomal arm 8q are shown in Supplementary Figure 1. d, Inferred evolution of 
case A11 with mutations shared among all samples forming the trunk, and mutations not 
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present in all samples forming the branches. The length of the trunk and branches is scaled 
by the total number of mutations in the samples.
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Figure 2 |. The spectrum of driver mutations in uveal melanoma.
Multi-region sequencing of primary and matched metastases was performed on tumors from 
35 patients. The spectrum of driver mutations (rows) in all patients (columns) is shown. 
Gain/change-of-function and loss-of-function mutations are respectively indicated as red or 
blue tiles. Mutations present in every sequenced region from a given patient are portrayed by 
solid tiles, and mutations present in only a subset of tissues from a given patient are 
portrayed by faded tiles. Mutations are grouped into three categories based on their deduced 
order of emergence during progression: primary drivers (shared and fully clonal), secondary 
drivers (shared and usually clonal), and tertiary drivers (private to later stages and typically 
subclonal).
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Figure 3 |. Mutations disrupting chromatin remodeling factors emerge throughout the 
progression to metastatic disease.
a–c, Exemplary phylogenetic trees in which BAP1 loss emerged early (a) and late (b,c). In 
cases with early loss, bi-allelic loss-of-function mutations reside on the trunks of the trees, 
whereas in cases where it arose later, at least one hit is situated on a branch. d, Dual 
immunostaining for BAP1 (brown) and melan-A (red) demonstrates that A13 and A29 
metastases are null or BAP1 protein. e, Cases in which mutations in other chromatin 
remodeling factors were detected. These alterations tended to arise later, positioning them on 
the branches.
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Figure 4 |. Gene dosage of chromosome 8q increases during progression.
a, Examples of phylogenetic trees in which gains of 8q occur early and subsequently 
increase (see Supplementary Figs. 1b and 4 for more details on these copy number 
alterations). b, Examples of phylogenetic trees of tumors in which metastatic dissemination 
preceded gain of 8q. The detailed evolution of each case is available in the supplementary 
dataset (see Methods). c, Copy number increase of 8q in metastases and primary tumors is 
shown on the y-axis, with 0 reflecting the normal, diploid state. Red bars denote averages, 
indicating that in our cohort the level of 8q copy number increase doubled from primaries to 
metastases (P = 0.002, two-tailed t-test).
Shain et al. Page 20
Nat Genet. Author manuscript; available in PMC 2019 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5 |. The sequential order of genetic alterations during metastatic progression.
a, Top panel: the y-axis indicates the relative fraction of patients in which the indicated 
somatic alterations occupied the trunk or branches of their respective phylogenetic trees. 
Somatic alterations that were more common in the trunks of phylogenetic trees were 
assumed to undergo selection earlier than those situated on their branches. Bottom panel: the 
number of patients with each of the indicated somatic alterations. b, Enrichment scores (P-
values) were calculated using a two-tailed binomial test (see Methods for details) for the 15 
genetic alterations highlighted in a to determine whether they were more common in 
primary tumors (n = 53) or in metastases (n = 36). Vertical gray lines indicate P-values of 
0.05. Scores were calculated under the assumption (null hypothesis) that somatic alterations 
are equally distributed between primaries and metastases. Most somatic alterations were 
enriched in metastases, though only 6q loss, gain of at least 3 copies of 8q, and gain of 1q 
reached statistical significance.
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Figure 6 |. The evolution of metastatic uveal melanoma.
‘CNA’, copy number alteration. ‘Other CNAs’ include combinations of 16q loss, 8p loss, 6q 
loss, or 6p gain, among others. ‘Additional pathogenic mutations’ include various 
combinations of 8q amplification, 1q gain, CDKN2A loss, SWI/SNF mutations, and EZH2 
mutations, among others. The precursors to primary uveal melanoma are not well 
understood, as reflected here by the questions marks adjacent to those clinical stages in our 
model.
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